Sodium- and chloride-dependent glycine transporter 1

Sodium- and chloride-dependent glycine transporter 1, also known as glycine transporter 1, is a protein that in humans is encoded by the SLC6A9 gene which is promising therapeutic target for treatment of diabetes and obesity.

Selective inhibitors

Elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. Several drug candidates have reached clinical trials.

ASP2535
Bitopertin, which has entered phase II trials for the treatment of schizophrenia
Iclepertin by Boehringer Ingelheim which is thought to improve cognitive impairment due to schizophrenia
Org 25935
PF-03463275
Pesampator by Pfizer
Sarcosine which is thought to improve cognitive impairment due to schizophrenia

Pathological mutations

Mutations of the gene may cause a severe metabolic disorder discovered in 2016 and called glycine encephalopathy with [normal serum glycine], also known as GlyT1 encephalopathy.